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Stlmmary 
Hen egg lysozyme 52-61-specific CD4 + T cells responded by interleukin 2 (IL-2) secretion to 
any peptide containing this epitope regardless of length of NH2- and COOH-terminal compo- 
sition.  However, CD4-  variants could only respond to peptides containing the two COOH- 
terminal tryptophans at positions  62 and 63. Substitutions  at these positions  defined patterns 
of reactivity that were specific for individual T  cells inferring a T cell receptor (TCR)-based 
phenomenon. Thus, the fine specificity of major histocompatibility complex (MHC)-peptide 
recognition by the TCR was dramatically affected by CD4 and the COOH-terminal peptide 
composition. Peptides that failed to induce IL-2 secretion in the CD4-  variants  nevertheless 
induced strong tyrosine phosphorylation of CD3~'. Thus, whereas the TCR still recognized and 
bound to the MHC class II-peptide complex resulting in protein phosphorylation,  this interaction 
failed to induce effective signal transduction manifested by IL-2 secretion. This provides a dear 
example of differential signaling mediated by peptides known to be naturally processed. In addition, 
the external domains of CD4, rather than its cytoplasmic  tail, were critical in aiding TCK recognition 
of all peptides derived from a single epitope. These data suggest that the nested flanking residues, 
which are present  on MHC class II but not class I bound peptides,  are functionally relevant. 
T 
he TCR recognizes foreign antigens in the form of short 
peptides bound to MHC class I or II molecules (1-3). 
Peptides bound to MHC class I are relatively length restricted 
and typically only one peptide will derive from a single epi- 
tope (4-6).  In contrast, MHC class II bound peptides  are 
heterogeneous in length, and epitopes are frequently presented 
as large numbers of peptides  nested at both the NH2- and 
COOH-termini (7-10). These differences could have signi- 
ficant consequences for TCIL recognition. Whereas only a 
few side chains in the center of MHC class I bound peptides 
would be accessible to the TCR (11-14), the extension  of 
bound peptides at either end of the MHC class II molecule 
(3) raises the possibility that these flanking regions may affect, 
or directly interact with, the TCR. However, there is nei- 
ther evidence nor precedence for this notion (15-17). 
A close association between CD4 and the TCR-CD3 com- 
plex is thought to occur during antigen presentation  as a re- 
sult of their interaction with the same MHC class II mole- 
cule (18, 19). Early speculation  that CD4 may play a role 
in T cell activation came from the observation that cocross- 
linking CD4 with the TCR-CD3 complex resulted in a syn- 
ergistic response (20, 21). More recently, supporting evidence 
has come from cocapping,  comodulation, and fluorescence 
energy transfer experiments (22-26). Indeed, certain antidono- 
typic antibodies have been shown to induce the comodula- 
tion of CD4 with the TCR in the absence of cross-linking 
by secondary antibody (22, 24). However, none of these data 
can rule out the possibility that this association occurs via 
an intermediate molecule rather than via direct binding be- 
tween CD4 and the TCR. Whereas attempts to demonstrate 
direct physical contact have been largely unsuccessful (27), 
suggestive evidence has come from two recent studies using 
affinity chromatography of 12SI-labeled  proteins (28), and an 
in vitro kinase assay (29). These difficulties may be due to 
the instability of this interaction (29, 30). Whereas only 5% 
of CD4 is associated with the TCR on a resting cell (31), 
up to 30% of the CD4 molecules comodulate with the TCR 
after specific antigen stimulation (32). 
Despite these uncertainties, even  an indirect association may 
be functionally important. Support for this notion has come 
from the identification of a src tyrosine kinase, p56 ~k, which 
associates with the cytoplasmic tail of CD4 (33-35).  Induc- 
tion of CD4-TCR association with certain anticlonotypic 
antibodies (36) or in vitro kinase assays with p56~k-immuno  - 
precipitates (29) results in the phosphorylation of CD3e and 
CD3~" (also known as TCR~). However, p56  ~k has also been 
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during T cell activation (37). Although previous studies have 
suggested  that  neither  effective  T  call  stimulation  nor 
CD4-TCR association can occur when CD4 cannot associate 
with p56  ~k (38-41), recent studies have implied an opposing 
view with p56  kk playing a critical  role in TCR-mediated fig- 
naling and T cell development in vivo in the absence of cou- 
pling  to CD4  (42-44). 
The physiological consequences of CD4-TCR interaction 
on TCK function are not dear. This question has previously 
been addressed using  CD4 loss variants  of three different 
H-2Ak-restricted routine T  cell hybridomas specific for the 
immunodominant  hen egg lysozome (HEL) 1 peptide 52-61 
(45).  Whereas  all  the  CD4 +  and  CD4-  variants  tested 
responded comparably to immobilized anti-TCR and anti- 
CD3 mAbs and naturally processed HEL, only the CD4 + 
hybridomas responded to the synthetic tryptic peptide 46- 
61. These data suggested that class II-restricted T  cells can 
only recognize a limited repertoire of peptides in the absence 
of CD4,  and  that  at  least  some naturally processed HEL 
peptides can stimulate CD4- hybridomas. The recent iden- 
tification of multiple nested peptides containing the core se- 
quence 52-61, extracted from HEL-pulsed, H-2A  ~ positive 
B cells lends credence to this notion (46, 47). Furthermore, 
the role of CD4 and different naturally processed nested pep- 
tides in differential signaling through the TCK remains to 
be defined (48-52). 
The initial aim of this study was to determine which among 
all the possible peptides containing the HEL 52-61 epitope 
stimulate the CD4-  T cell hybridomas. These experiments 
led to the identification of two residues, Trp 62 and Trp 63, 
that are essential for TCR recognition in the absence of CD4. 
As a result, the following questions have been addressed. First, 
do peptides containing these residues have a higher affinity 
for either MHC class II molecules or TCIL? Second, what 
is the sensitivity of TCR recognition to amino acid substitu- 
tions at these residues? Third,  with CD4 loss variants that 
fail to respond in the absence of these residues, does the TCR 
still ligate the MHC-peptide complex? Fourth, what effect 
do these residues and the absence of CD4 have on signal trans- 
duction? Fifth, what regions of CD4 aid in TCK recogni- 
tion  of peptides that  lack these residues? 
Materiah and Methods 
Peptides.  A nested set of 53 peptides consisting of every pos- 
sible 12-19 mer that contains the minimal MHC binding epitope 
52-61 (53, 54), was synthesized by Chiron Mimotopes (Melbourne, 
Australia) using pin synthesis technology. Peptides were dissolved 
in 10% DMSO in HzO at -~100/zM.  Because of variable solu- 
bility and approximate quantitation,  these peptides were only used 
for qualitative analysis. 
Crude analog peptides (see Table 2) were obtained from Chiton 
Mimotopes, purified to 95 % by reversed-phase HPLC, and ana- 
lyzed for integrity,  composition,  and concentration  using  mass 
1  Abbreviations used in this paper: HEL, hen egg lysozome; lP, inositol 
phosphate; PLC, phospholipase C. 
spectrometry and quantitative amino acid analysis as previously de- 
scribed (10). 
Murine T Cell Hybridomas and Transfectants.  CD4* and CD4- 
variants of 3A9 (P4, N49: in all cases P denotes cells which express 
CD4 and N denotes ceUs which lack CD4), A2.2B2 (P2, N22), 
2135.1 (PS, N3), and A167 (1%7, N54), were isolated as previously 
described (45, 55) except that a different 3A9 clone, N49 rather 
than N30, was used as the latter, which failed to respond to HEL, 
was subsequently found to be unable to regain response to HEL 
after transfection with wild-type CD4. Variants from 4G4.1 (P5, 
N4) and 1C5.1 (P16, N1) (both generous gifts from ~dano Adorini, 
Roche Mihno Ricercbe, Milan, Italy) were isolated for this study. 
Briefly, hybridomas were double labeled with GK1.5 biotin (anti- 
CD4) followed by streptavidin-PE (Caltag Laboratories, San Fran- 
cisco, CA) and anti-CD3-FITC (GIBCO BRL, Gaithersburg, MD). 
CD4 + and CD4-  cells with  equivalent  TCR-CD3  expression 
were sorted at one cell per well (Epics 750 series with Autoclone 
attachment; Coulter, Hialeah, FL). After 2 wk, approximately 24 
clones were tested for CD4 and equivalence of TCR, CD2, LFA-1, 
CD45,  CDS, LFA-1, and CD28 expression by flow cytometry 
(FACScan  |  Becton Dickinson, San Jose, CA). At least six of these 
were then tested for their equivalence of sensitivity (i.e., between 
CD4 + and CD4- clones) to immobilized anti-TCR (H57.157), all 
of which gave comparable results (45). 
A construct that produces CD4 molecules that lack an intact 
cytoplasmic domain (CD4.ACY) was generated by exchanging T 
for C  at  bp  1,312, thereby  producing  a  stop  codon  (Vignali, 
D. A. A., unpublished results). This leads to a cytoplasmic tail of 
only five amino acids (Arg Cys Arg His Asu; 56). This short tail 
is required to retain CD4 in the membrane. The full-length wild- 
type mouse CD4 cDNA (CD4.WT) and CD4.ACY were sub- 
cloned into pH3Apr-lneo (human 3-actin promoter; 57), and trans- 
fected into the 3A9 and A2.2B2 CD4 loss variants as previously 
described (45). The CD4.ACY transfectants were shown to lack 
a functional cytoplasmic tail by the inability of anti-CD4  mAb to 
coimmunoprecipitate  p56 ~k  (Vignali, D.  A.  A.,  unpublished 
results). 
Antigen Presentation Assays.  Assays  were performed essentially 
as described elsewhere (45, 55). Briefly, T cell variants (5  x  104, 
100/zl) were cultured  with 2.5  x  104 (100 #1) LK35.2 (routine 
B cell lymphoma,  H2-A  ~) in  flat-bottomed  96-well microtiter 
plates with synthetic peptides or HEL (Sigma Chemical Co., St. 
Louis, MO) at the concentrations indicated. Supernatants (50/zl) 
were removed after 24 h for estimation  of II~2 secretion by cul- 
turing with the Ib2-dependent T cell line CTLb2 (5  x  104; 50 
/A).  Proliferation  was  determined  by using  a  methyl  thiasol- 
tetrazolium (MTT) assay according to the manufacturer's instruc- 
tions (Promega, Madison, WI). IL-2 concentration was determined 
by using murine rIL-2 (Genzyme Corp., Cambridge, MA) as a stan- 
dard. ECs0 values were determined  by titrating  peptides  10-fold 
from 10/zM to 100 pM, calculating the number of IL-2 U for each 
dilution  from a rlL-2 standard. 
H-2A~-peptide A~nity Assay.  Affinity of the HPLC-purified 
analogs was determined by competition with biotinylated HEL 46- 
61. H-2A  ~ (50 nM in 100/A) was purified as previously described 
(47) and was incubated with 100 nM HEL 46-61 biotin and com- 
petitor peptide from 10/zM to 30 nM at room temperature  for 
48 h in Mcllvaine citrate/phosphate  buffer, pH5 (58), in 96-weU 
plates that had been preblocked for 24 h with blocking buffer (3% 
BSA, 0.1% Tween 20, 0.02% NaN3 in PBS, pH 7.2). 20/A 1 M 
NazHPO4 and 30/~1 10% BSA were added to the reactions and 
transferred to plates that had been previously precoated with anti- 
H-2A  k (10.2.16 at 10/~g/ml) for 24 h, washed, and then incubated 
1946  TCR Recognition with blocking buffer for 2 h. After 90 min,  plates were washed 
and  probed  with  streptavidin-alkaline  phosphatase  (1:1,000 in 
blocking buffer; Bio-Rad, Hercules, CA). Ki values are defined as 
the concentration  of inhibitor  required to give 50% inhibition  of 
46-61 biotin. 
InositoIPhosphate  Assay.  LK35.2 cells were pulsed with the ap- 
propriate peptides at 3/zM final overnight,  and washed once in 
PBS before  use. Hybridomas were labeled  at  107/ml with  40 
/~Ci/ml [3H] myo-inositol (23.45 Ci/mmol; NEN DuPont, Wil- 
mington, DE) at 37~  for 3 h. Cells were washed three times with 
inositol-deficient RPMI 1640/10% FCS containing  10 mM LiC1. 
An  aliquot  (5  x  10  s cells) was  taken  for liquid  scintillation 
counting (15 ml Aquasol; NEN DuPont) to determine  the total 
[SH] myo-inositol  incorporation.  An  equal  number  (5  x  10  + 
cellsAample) of LK35.2 and T cell hybridomas were mixed and 
spun at low speed for I rain in a microcentrifuge  to promote cell 
contact  and incubated  at 37~  for 10 min. 
Medium was removed and cells lysed with 1 ml ice-cold 10% 
TCA, vortexed, and left at 4~  for 30 min.  Samples were spun 
for 10 min in a microcentrifuge,  TCA extracted five times with 
1 ml H20-saturated ethyl ether, neutralized with 40/zl of 1:100 
ammonium  hydroxide, and diluted  to 4 ml with H20. Samples 
were loaded onto a 1-ml AG1-X8 anion exchange column (100-200 
mesh, formate form; Bio-Rad) and washed with 50 ml of 60-mM 
sodium formate/5-mM  sodium borate. Inositol phosphate (IP) was 
eluted with 15 ml of 1 M ammonium formate/0.1  M formic acid. 
Aliquots  of each eluate (2 ml plus 16 ml Aquasol) were counted 
in a liquid  scintillation counter. 
Tyrosine Phosphorflation Analysis.  Peptide-pulsed LK35.2 cells 
(5  x  10  + cells/sample) were prepared as for the IP assay, mixed 
with T cell hybridomas (107 cellsAample), spun at low speed for 
1 min in a microcentrifuge"  and incubated  at 37~  for 5 rain. 
Medium was removed and the cell pellet lysed with 500/zl lysis 
buffer containing  1% NP-40 (Fluka, Ronkonkoma,  NY), 20 mM 
Tris-HC1, pH 7.4, 150 mM NaC1, 5% glycerol, enzyme inhibitors 
(2 mM Pefablock [Centerchem,  Stamford, CT], 25/zM aprotinin, 
25/~M leupeptin),  and phosphatase inhibitors  (2 mM sodium or- 
thovanadate"  2  raM  sodium  fluoride,  10  mM  tetrasodium 
pyrophosphate,  1 mM EDTA). Lysates were left at 4~  for 1 h, 
spun for 15 min in a microcentrifuge,  and precleared twice with 
50/zl of a 10% suspension of Pansorbin (Calbiochem-Novabiochem 
Corp., San Diego, CA). Two methods ofimmunoprecipitation were 
used. (a) Protein A-Sepharose beads (RepliGen, Cambridge, MA) 
were precoated for 2 h at 4~  with either rabbit anti-PLC~l an- 
tisera (8 #1/107 cells; Upstate Biotechnologies  Inc. [UBI], Lake 
Placid, NY, or 20/zl/107 cells; Santa Cruz Biotechnology, Santa 
Cruz, CA) or rabbit anti-CD3~" antisera (3/~1/107 cells; No. 387, 
gift from Larry Samelson, National Institutes of Health, Bethesda, 
MD). Beads (25/~1) were added to lysate and rocked at 4~  over- 
night.  (b) Antibody was added to lysates and rocked at 4~  over- 
night. Protein A-Sepharose beads were then added and the samples 
rocked for an additional 2 h. Samples were washed twice with lysis 
buffer  and once in modified lysis buffer with 0.1%  NP-40 and 
without glycerol. Ehted proteins were resolved on either an 8%, 
for PLC~/1, or a 12%, for CD3~', SDS-PAGE gel, and transferred 
onto nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, 
NH). 
Blots were blocked with 5% BSA (American Bioanalytical, Na- 
tick, MA) in TBS-T (0.2% Tween 20, 10 mM Tris-HC1, pH 8, 
150 mM NaC1) at 4~  overnight.  Tyrosine phosphorylation  was 
detected with a biotinylated mAb 4G10 (0.1/~g/ml; UBI), followed 
by a 1:40,000 dilution of streptavidin-horseradish peroxidase (HRP) 
preformed complexes (Amersham, Arlington  Heights,  IL). Blots 
were developed using enhanced chemiluminescence (Amersham). 
To detect the original protein, blots were stripped in 100 mM 2-ME 
(Bio-Rad), 2% SDS, 62.5 mM Tris-HC1, pH, 6.7, for 30 min at 
50~  washed three times and blocked with 5% nonfat dry milk 
in TBS-T at 4~  overnight. Blots were probed with either mixed 
anti-PLC3~l mAbs (0.5/~g/ml;  UBI) or rabbit anti-CD3~" antisera 
(1:200), followed  by either sheep anti-mous~HRP (1:40,000; Amer- 
sham) for PI.C~/1 blot, or protein A-HRP (1:20,000; Amersham) 
for CD3~" blot. Blots were developed as above. 
Some TCRs Can Only Recognize a Limited Number of  Naturally 
Processed Peptides in the Absence of CD4 
Loss of CD4 Dramatically Affects the Response of Some but 
Not All T  Cells to Peptides.  A  pand of CD4 + and CD4- 
murine T cell hybridomas was used to study the role of CD4 
in modulating the ability of the TCR to recognize peptides 
containing  NHz- and COOH-terminal  extensions of HEL 
52-61. Of the hybridomas listed in Table 1, all except for the 
1C5.1 variants,  which were produced for this study, have been 
previously described (45, 47).  A  nested set of 53 peptides 
consisting of every possible 12-19 mer that contains the min- 
imal MHC binding epitope, HEL 52-61 (53, 54) was made 
(Fig.  1). It should be noted that these were produced using 
pin-synthesis technology which facilitates the production of 
a large number of peptides.  However, since they are crude 
and quantification is approximate, they were used solely for 
qualitative functional assessments. 
All the CD4 + hybridomas responded strongly to all the 
peptides regardless of length or composition, with the ex- 
ception of the shortest peptides,  which stimulated weaker 
responses by some of the dones (Fig. 1, stippled burs). In con- 
trast, the ability of the CD4- hybridomas to recognize these 
peptides fell into three distinct phenotypes (Fig. 1, solid bars; 
Table 1).  In phenotype A,  exhibited by A2.2B2,  3A9 and 
4G4.1,  the only peptides that could stimulate a strong re- 
sponse were those that extended at least to Trp 63 (Trp/W) 
(e.g., peptides 52-63). In addition, this response fell off sharply 
with successive COOH-terminal  extensions.  In phenotype 
B, exhibited by A167, a single Trp at position 62 was sufficient, 
whereas in phenotype C, exhibited by 1C5.1 and 2B5.1, loss 
of CD4 had no effect on peptide recognition. Increase in pep- 
tide length  at the NH2-terminus  had little effect. 
These observations do not merely define the difference be- 
tween CD4-dependent  and -independent hybridomas as all 
the CD4 loss variants,  regardless of phenotype, responded 
strongly to naturally processed HEL (Vignali,  D.,  unpub- 
lished results). Why then are some but not all T cell hybrid- 
omas sensitive to the loss of CD4? No obvious correlation 
between CD4 requirement and the sensitivity of the hybrid- 
omas to HEL or TCR-VotVI3 usage was seen (Table 1). Al- 
though 4G4.1 was 10 times more sensitive than 2B5.1, it was 
the former rather than the latter that was affected by the loss 
of CD4. Furthermore, these hybridomas were not dependent 
on costimulatory signals as fixed B cells were efl~dent APCs, 
and the presence or absence of CD28 had no effect (data not 
1947  Vignali  and Strominger Table  1.  Characteristics  of the HEL 52-61-specific Murine T  Cell Hybn'domas 
Restriction  HEL  Residue 
Phenotype  Hybridoma  element  TCR Vc~V/~ Usage  ECs0 (#M)  dependence 
A  3A9  H-2A k  Voz3  V/~8.2  10 -1  Trl0 62 and Trp 63 
A2.2B2  H-2A k  Vo~11  V/~5.2  10-]  Trp 62 and Trp 63 
4G4.1  H-2A k  Vow4  VB8.3  3  x  10 -2  Trp 62 and Trp 63 
B  A167  H-2Acr  b  Vcr  V/38.3  10 -~  Trp 62 
C  1C5.1  H-2A  ~  Vex2  V~6  10- ~  None 
2B5.1  H-2A k  Vod  V/~8.2  3  x  10 -~  None 
The phenotype of the hybridomas was determined by the requirement of the CD4-  variants for Trp 62 and Trp 63 (residue dependence) derived, 
in part, from Fig. 1. TCR VotVB usage was determined either by flow cytometry and dot blot analysis using specific Vo~ and V~ probes (performed 
by Gaff Cole, Sherri Surman and David Woodland, St. Jude Children's Research Hospital, Memphis, TN) or from the literature (45, 59, 90). HEL 
ECs0 refers to the concentration of HEL required to give 50% stimulation. Data represent a rounded average of three to six experiments. 
shown). Thus, the way in which a given TCK interacts with 
the peptide-MHC complex probably governs its requirement 
for CD4.  Perhaps of greater interest  are those hybridomas 
that respond to some but not all peptides in the absence of 
CD4 (phenotype A), and it is these hybridomas that are the 
focus of this study. In summary, these CD4 loss variants re- 
spond to HEL and the minimal epitope 52-63, but not, for 
example, to 52-61 or 52-62. In contrast,  the CD4 + hybrid- 
omas responded to all of these peptides. 
COOH-terrainal Peptide Residues Differentially Affect TCR 
Interaction.  Two questions arise from the results above. First, 
could these data be explained on the basis of peptide affinity 
for H-2A k or TCK, and second, how tolerant is the TCR 
to amino acid substitutions at Trp 62 and Trp 63? These ques- 
tions were addressed using a second panel of HPLC-purified 
peptides,  all of which began at the NHz-terminus at posi- 
tion 48  (Table 2).  This  residue  is  the most  predominant 
NH:-terminus present in naturally processed peptides  (46, 
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Figure  1.  The loss of CD4 has contrasting effects on responsiveness to HEL 52-61 nested peptides. Peptides were synthesized  and antigen presentation 
assays performed as described in Materials and Methods. Sequences of peptides are denoted on the left with the boxed sequence indicating the Inlni'qlal 
H-2AL-binding epitope (53, 54). A representative of each phenotype (.4, B, or C) is shown. Other members of each phenotype have similar profiles 
and are described in Ihble 1. Peptide concentrations were either 10 #M (A2.2B2 and IC5.1) or 1 I~M (A167). (*) DMSO negative contrd. Data are 
representative of four experiments. Single letter abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; F, Phe; G, Gly; L Ile; L, 
Leu; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; W, Trp; and Y, Tyr. 
1948  TCR Recognition Table  2.  HEL 48-61 Analog Peptides and their Affinity 
for H-2A k 
Analog  Peptide 
Peptide  Sequence 
Ki 
against 
HEL 
46-61 
biotin 
(100 nM) 
uoNl* nesMmmsvun*eel  um~m 
48-61  DGST~OXv-QvmSm  449~89 
48-61W  DGSTD'/GZ~ZNSRW  414• 
48-6  IWW  DGSTDMGILQI~BRWW  550~  142 
48-61WWC  DGSTDYGZLQINBRW~C  454• 
48-61VCWCN  DGSTDYGILQINBRWWCN  509~48 
48-61WWA  DGSTD%'GILQImBRWWA  1026• 
48-61W3VAA  DGSTDYGIL(}INSRWWAA  967• 
48-61A  DGSTDYGILQTNBRA  478• 
48-61AA  DGSTDYGILQImSRAA  666~ 138 
48-61WA  DGSTDYGILQI~SRWA  651• 
48-61AW  DGS ~lff'Z~I~INWRAW  651+57 
48-61F  DGSTDYGILQINSRF  671 • 
48-61FF  DGSTDYGILQZtlSRFF  801• 
48-61WF  DGSTDYGILQINBRWF  570• 134 
48-61FW  DGSTD%'GILQZNSRFW  511 • 164 
48-61 FA  DGSTDYGIL~INSRFA  784+209 
48-61AF  DGSTDYOZLQXI~SRAF  578• 
48-61QQ  DGSTI~tO'r  LQ'rmSRQQ  475• 121 
48-61-~A-~A  DG  STDIfOI  LQINBR~nA~xA  771• 
Affinity of the HPLC-purified  analogs was determined by competition 
with biotinylated HEL 46-61. Ki values are defined  as the concentration 
of inhibitor required to give 50% inhibition of 46-61 biotin. Ki values 
of controls were: HEL 46-61, 345 +  91; RNase 43-56 (lower affinity 
for H-2Ak), 3,535 _+ 795; HEL 1-18, >104; HEL 105-120, >104 (the 
last two peptides bind to H-2E  k but not to H-2Ak). See legend to Fig. 
I for single amino acid code. Data represent the mean and standard error 
of three experiments  each performed  in duplicate.  ~nA, 15-naphthylalanine. 
47).  One set of peptides consisted of COOH-terminal  ex- 
tensions of the natural sequence from position 61 to 65, with 
two additional peptides possessing alanine (Ala/A) substitu- 
tions at positions 64 and 65.  A  second set of consisted of 
Ala, phenylalanine (Phe/F), ghtamine (Glu/Q), and ~-naph- 
thylalanine (~-nA) substitutions of Trp 62 and Trp 63. These 
substitutions were chosen in an attempt to delineate the two 
functional interactions afforded by tryptophan, namely bulky 
hydrophobicity and hydrogen bonding capacity. A particu- 
larly interesting substitution was ~-naphthylalanine, which 
is a large, bulky, planar hydrophobic amino acid like trypto- 
phan, but which lacks the N-H group required for the for- 
mation of hydrogen bonds. 
The affinity of these peptides for H-2A k was determined 
using a competition peptide binding assay (Table 2). Using 
this method, no significant difference in peptide affafity could 
be found between the peptides, except for 48-61WWA and 
48-61WWAA,  which  had  slightly  lower  affinities.  Most 
notably, the affinity of 48-61 and 48-61WW (48-63) was iden- 
tical. Thus, peptide affinity for MHC class II molecules does 
not explain the differences observed. 
In functional assays, the original observation was faithfully 
reproduced using these highly purified peptides (Fig. 2 A). 
Whereas the CD4 + clones isolated from the three pheno- 
type A hybridomas, A2.2B2, 3A9, and 4G4.1, responded to 
all  the  COOH-terminal  extended peptides  (48-61  to  48- 
61WWCN),  albeit to varying degrees, the CD4 loss vari- 
ants only responded to COOH-terminal extensions that con- 
tained Trp 63. In previous experiments using the nested set 
of peptides, the response of CD4-  hyridomas fell off dra- 
matically with the subsequent COOH-terminal addition of 
Cys 64 and Ash 65 (Fig.  1). However, using purified pep- 
tides and alanine analogs at these residues (48-61WWA and 
48-61WWAA),  this observation could not be satisfactorily 
duplicated. Indeed, with all three hybridomas, the response 
of both the CD4 + and CD4-  hybridomas declined propor- 
tionally. Thus, the previous observations were more likely 
attributable to differences in quantitation due to poor solu- 
bility of the crude peptides. 
Each of the three phenotype A CD4 loss variants responded 
differently to the tryptophan-substituted analog peptides (Fig. 
2 B). The 3A9 CD4 loss variant failed to respond to any of 
the analogs except for a moderate response to 48-61WA and 
a marginal response to 48-61WF, inferring a strict require- 
ment for both tryptophans, particularly Trp 62. On the other 
hand, the A2.2B2 CD4 loss variant responded to 48-61WF 
and 48-61FW but to none of the other analog peptides, sug- 
gesting that a single tryptophan in either position plus a hy- 
drophobic amino acid is required for stimulation. In contrast, 
the 4G4.1 CD4 loss variant was more tolerant to COOH- 
terminal variation, responding to 6 of the 10 analogs, although 
with some preference for Trp 63. It is interesting to note that 
the response by the CD4 + 4G4.1  hybridoma to 48-61AW 
was 100 times more sensitive than its response to 48-61WW. 
Thus, single amino acid substitutions in flanking regions out- 
side the minimal MHC binding epitope can have a dramatic 
effect on T cell responsiveness. Furthermore, the clearly dis- 
parate recognition patterns of the three CD4 loss variants 
infers a TCR-  rather than MHC-based phenomenon. 
Differential Signaling: TCR Ligatio,  in the Absence of 
IL-2 Secretion 
A  Role for the Extracelhlar Domains of CD4.  Two intrig- 
uing questions are posed by these data. First, does the TCR 
still bind to dams II molecules containing peptides that fail 
to induce IL-2 secretion by the CD4-  hybridomas? Second, 
is the ability of CD4 to compensate for the defect in IL-2 
secretion linked to its intrinsic association with p56~k? To 
address these questions, a variety of signal transduction events 
were analyzed in response to 46-61, 46-61WW, and 46-61FF 
1949  Vignali  and Strominger Figure 2.  Differential  ability  of 
CD4 loss variants to respond to 
analog  peptides.  Peptides  used  in the 
antigen  presentation assay are 
detailed in Table 2, and were pre- 
pared as described  in Materials  and 
Methods. (,4) Includes COOH- 
terminal extensions  of the natural 
sequence and  two  analogs con- 
taining ahnine  substitutions  at Cys 
64 and Ash65. (/3)  Includes  peptide 
analogs  containing  substitutions  of 
Typ 62 and Trp 63. Peptides  were 
titrated from 101 to 10 .4 #M and 
the data presented  as ECs0, which 
is the concentration  of  peptide  that 
gives 50%  stimuhtion. Data are 
presented as the mean of two ex- 
periments performed  in duplicate. 
(peptides slightly longer at the NH2-terminus were used in 
order to improve peptide solubility). The CD4 + 3A9 T cell 
hybridoma was chosen for further study as it responds com- 
parably to 48-61WW and 48-61FF  (within t/21ogt0; Fig.  2). 
Transfection of the 3A9 CD4 loss variant (CD4-)  with 
either wild-type CD4 (CD4 +) or a cytoplasmic-tailless  CD4 
(CD4.ACY) restored its ability to respond to both 46-61 and 
46-61FF (Fig. 3 A). Identical results were obtained with trans- 
fectants of the A2.2B2 CD4 loss variant (data not shown). 
Multiple clones of the CD4.ACY transfectants were shown 
to consistently respond to all peptides and failed to coim- 
munoprecipitate p56 ~  with CD4  (data not shown). 
Ligation of the TCK-CD3 complex initiates an array of 
second messenger events in addition to the secretion of IL-2. 
One of the best studied is the hydrolysis of phosphatidylino- 
sitol 4,5-bisphosphate by phospholipase C (PLC) to generate 
the intracellular second messengers, inositol 1,4,5-trisphosphate 
(IP3), which mobilizes intracellular calcium stores,  and 1,2- 
diacylglycerol, which activates  protein kinase C  (59).  The 
generation of total IP by the CD4 + and CD4-  hybridomas 
correlated with IL-2 release, although 46-61 stimulated weaker 
IP production (Fig.  3 B).  Surprisingly, the IP profile pro- 
duced by the CD4.ACY transfectant was more akin to that 
observed with the CD4 loss variant, despite the induction 
of strong IL-2 secretion by all peptides.  This is consistent 
with previous findings which demonstrated that IP produc- 
tion is not a prerequisite for IL-2 secretion (60). 
Two of the most characterized and predominant proteins 
that are tyrosine phosphorylated after TCK engagement in- 
clude the PLC3,1 isoform and the CD3~" chain (also known 
as  TCK~)  (61,  62).  The latter  is  an  integral  part  of the 
TCR-CD3  complex and has been shown,  in isolation,  to 
be suf~dent for T cell activation (63-65). As expected, strong 
phosphorylation of both proteins was observed when the 
CD4 + transfectant was stimulated with any peptide, whereas 
none was observed in the absence of peptide (Fig. 3 C). The 
two CD3~" bands observed could represent phosphorylation 
at either four or all six of the available tyrosine residues, with 
the upper band probably the hyperphosphorylated pp22 (66). 
The pattern of tyrosine phosphorylation did not correlate 
with IL-2  secretion in  either the CD4 loss  variant or the 
CD4.ACY transfectant. With the former, strong phosphory- 
lation of CD3~" was observed with all peptides even though 
only 46-61WW induced detectable IL-2 secretion. Only the 
lower CD3 ~" species was induced by all the peptides, whereas 
the detection of the hyperphosphorylated CD3~" and PLC3~I 
phosphorylation more closely mimicked IL-2 secretion. Thus, 
it is possible that the two phosphorylated forms of CD3~" 
play different roles. Most interestingly, significant CD3~'phos- 
phorylation in the CD4 loss variant occurred after stimula- 
tion with either 46-61 or 46-61FF, providing strong evidence 
for TCK engagement despite the complete absence of IL-2 
secretion. 
The CD4.ACY transfectant displayed an identical pattern 
of phosphorylation and IP rdease as the CD4 loss variant 
(Fig. 3, B and C), but possessed an IL-2 secretion profile more 
akin to the CD4.WT transfectant (Fig. 3 A ). These data clearly 
suggest that the cytoplasmic tail of CD4 needs to be present 
for PLC3'I phosphorylation to occur when T cells are stimu- 
lated with 46-61  or 46-61FF.  This is presumably mediated 
by  p56  ~k,  although  formal  proof  of  this  has  not  been 
presented. On the other hand, the role of p56  ~k after stim- 
ulation with 46-61WW cannot be fully determined. Although 
it is clear that PLC'y1 phosphorylation can occur in the ab- 
sence of the CD4 cytoplasmic tail, these data cannot rule out 
the involvement of p56 ~k as several studies have shown that 
it does not have to be associated with CD4 to exert its effect 
(42,  43). 
The important implications of these data are twofold. First, 
strong CD3~" phosphorylation occurs in the absence of IL-2 
secretion. This provides evidence of differential signaling in- 
duced by two peptides that are derived from a single epitope 
and that are known to be processed by APCs (47).  Second, 
the extracellular domains of CD4,  and not its cytoplasmic 
1950  TCK Recognition tail,  are responsible  for  the restoration  of IL-2  secretion  in 
response  to  46-61  and 46-61FF. 
Discordant  Dose-Response  of  CD3 ~  Phosphorylation  and IL-2 
Secretion.  Although there appears to be no correlation  be- 
tween CD3~"  phosphorylation and IL-2 secretion in the CD4 
loss variant,  it is possible that these events  occur at much 
lower ix'pride  concentrations than those required  for IL-2 secre- 
tion. Thus, 46-61WW might induce stronger  CD3~" phos- 
phorylation at much lower concentrations than 46-61FF. Pep- 
tide titration  experiments with the 3A9  CD4  transfectant 
Figure 3.  Analysis  of  signal 
transduction events in 3A9 transfec- 
tants.  The ability of 3A9 CD4-, 
CD4 +,  and CD4.ACY  transfec- 
tants to respond to HEL 46-61, 46- 
61WW, and 46-61FF  was analyzed. 
Identical  results  were  obtained  ff 
performed  with  Peptides  com- 
mencing  at  the  NH2-terminus 
with residue 48. (/1) IL-2 secretion 
was  determined  as  described  in 
Materials and Methods and data ex- 
pressed as ECs0. Peptides used are 
denoted as follows: (*) not deter- 
mined; (-) no Peptide added; (R) 
46-61 (R is used because Arg 61 is 
the  COOH-terminal  residue); 
(RWW)  46-61WW;  (RF~  46- 
61FF.  The horizontal dashed line 
marks the 3-/~M  peptide concentra- 
tion used in the experiments shown 
in B and C. Any bar substantially 
above this line represents maximal 
T cell activation at this concentra- 
tion. Data are representative  of three 
experiments. (/3) Total IP rdease was 
determined as described  in Materials 
and Methods.  Data represent  the 
mean and standard error of two ex- 
periments and are expressed as the 
percentage increase over 3H-inosi- 
tol-labeled T  cells alone. (C) The 
antibodies used for immunoprecip- 
itation and Western blot analysis  are 
indicated on the right. The meth- 
odology is described in Materials 
and Methods.  After detection  of 
phosphorylated  proteins, the same 
blots were stripped and redeveloped 
to detect total proteim  The minor 
band under PLC3,1 is the constitu- 
tively  phosphorylated  PLC'y2, 
which is coimmunopredpitated  be- 
cause of the mild crossreactivity of 
the antisera used. The two CD3~" 
bands are likely to represent  diiferent 
levels of tyrosine phosphorylation. 
The lower CD3~"  phosphoryhtion 
seen in the CD4.ACY transfectant 
is probably due to the lower level 
of total  CD3~" precipitated  from 
these cells. Data are representative 
of three experiments. (PO,) Su~ 
used to indicate the tyrosine phos- 
phoryhted species; (Tyr-PO4)  anti- 
phosphotyrosine  mAb. 
revealed a good correlation of CD3~" and PLC3'I phosphory- 
lation, with IL-2 secretion in response to either 46-61WW 
or 46-61FF (Fig. 4). However, whereas both peptides induced 
almost identical CD3~" phosphorylation profiles in the CD4 
loss variants, a complete absence of IL-2 secretion  and little 
PLC3,1 phosphorylation was observed after stimulation with 
46-61FF.  This experiment clearly defines two separable fig- 
naling events after TCR ligation, best illustrated by the dis- 
cordance  in CD3~" phosphorylation and IL-2  secretion  in- 
duced by 46-61FF in the CD4  loss variant. 
1951  Vignali and Strominger Figure  4.  Evidence  for TCR ligation  in the absence of II--2 secretion. (.4) The tyrosine  phosphorylation  of PLC3,1 and CD3~"  was determined  after 
stimulation  of the 3A9 loss variant (CD4-) and its CD4 + transfectant  with LK cells pulsed with the concentrations  of 46-61WW and 46-61FF indi- 
cated. Data are representative  of two experiments.  (B) Graphs represent  an overlay  of the data  from  (A), represented  as OD, determined  using  a densito- 
metric scanner  (PDI DNA35 scanner, Sparc station  IPC & Quantity  One V2.0 analysis  software;  Huntington  Station,  NY), with Ib2 secretion  induced 
with the same peptide concentrations.  It is important  to note that the protocol for peptide stimulation  used with these two protocols  is, of necessity, 
quite different, and thus only a relative, rather than direct, comparison  can be made. 
Discussion 
Three intriguing questions are raised by the data presented 
here. First, how is TCR recognition affected by Trp 62 and 
Trp  63?  Second, what effect does this have on TCR func- 
tion? Third, what is the role of CD4 in this process? 
How Is TCR Recognition  Affected by Trp 62 and Trp 63?  In 
the absence of CD4, Trp 62 and Trp 63 had a dramatic effect 
on the responsiveness  of four of the six T  cell hybridomas 
tested. Conversely, these differences were minimal in the pres- 
ence of CD4. Thus, these residues  may have a direct effect 
on the ability of the TCR to appropriately recognize the 
MHC-peptide complex. Whether this involves an alteration 
in the conformation of the MHC-peptide complex or direct 
binding to the TCR remains to be determined. 
One caveat to the former possibility is the fact that the 
Trp residues have no effect on peptide a~nity for MHC class 
II molecules, which one might have predicted if such an in- 
teraction were taking place. Whereas some data suggest that 
peptide residues  may affect MHC class I structure (14), it 
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is not yet known whether the same is true of class II mole- 
cules. Perhaps the best evidence in support of this idea is the 
observation that different Ix-prides affect the mobility of  MHC 
class II molecules in SDS-PAGE because  of the generation 
of either "floppy" or "compact" molecules (67,  68).  How- 
ever, recently it has been shown that HEL 46-61 and 46-63 
are both equally ef~cient at generating compact molecules 
(69). Another possibility is that the two Trp residues interact 
across the dimer junction proposed from the MHC class II 
crystal structure,  thereby stabili~,ing  the two dimers (3). How- 
ever, it seems more likdy that these two Trp residues are within 
the groove of the MHC class II molecule. Furthermore, it 
has not escaped our attention that the proposed placement 
of CD4 near the end of the peptide binding groove that con- 
tains the COOH-terminus of the peptide may be relevant. 
Does the TCR directly bind to the two COOH-terminal 
Trp residues?  Although current theoretical (15, 16) and ex- 
perimental (17) observations suggest that the peptide is bound 
by the CDR3 loops located in the center of the TCR, no data have yet been presented that demonstrate TCR binding 
to flanking peptide residues. However, the pattern of reac- 
tivity of the three bybridoma to the HEL 48-61 peptide analogs 
was quite distinctive, supporting the idea that these residues 
directly interact with the TCR. Indeed, recent studies (70) 
have suggested that the final configuration of TCR-MHC 
interaction is substantially affected by single amino acid sub- 
stitutions in the bound peptide. Whichever possibility turns 
out to be correct, its resolution is likely to be important in 
our understanding of this interaction. 
What Effect Does T~62/Trp 63 Have on TCR Function?  A 
plausible explanation  for these data is based on the affinity 
requirements for T ceU activation  (71, 72). In the presence 
of CD4, the collective avidity of the TCR binding to con- 
tact residues in the minimal peptide epitope and CD4 binding 
to MHC class II molecules, is suffident for the cell to remain 
above the threshold required for activation. However, in the 
absence of CD4, the Trp 62/63 residues become the limiting 
factor and their presence is a prerequisite for effective T cell 
activation.  Although the data are consistent  with this sce- 
nario, several observations are less easily explained solely on 
the basis of affinity requirements,  and they justify further 
investigation.  First, one might predict that T cells that pos- 
sessed the highest affinity TCR would not be dependent on 
CD4 for recognition of HEL 48-61, whereas the converse 
would be true for those with low affinity TCR. Surprisingly, 
the opposite is true as the two most sensitive T cell hybrid- 
omas are very sensitive to CD4 loss. Second, although the 
CD4- 3A9 T cell hybridoma failed to respond to most of the 
analog peptides, the CD4 + counterpart responded strongly 
to  most  as  several analog peptides  possessed ECso values 
similar to that for 48-61WW (within 1Alogl0: e.g., 48-61FF 
and 48-61QQ).  Whereas the resolution of these anomalies 
will extend our understanding of these delicate interactions, 
it will not affect the main conclusions  of this study. 
Several studies (48-52) have suggested that the TCR com- 
plex may possess the capacity for differential signaling. Per- 
haps only HEL 48-61WW can, in the absence of CD4, in- 
duce the "conformational change" required for complete signal 
transduction. Indeed, the demonstration of strong CD3~'chain 
phosphorylation in the CD4 loss variants  stimulated with 
48-62 despite no IP or IL-2 production, demonstrates  that 
a partial or inappropriate  signal is ddivered. An analogous 
situation also seems to occur in anergic Thl cells which fail 
to produce IL-2 upon antigen stimulation but which still 
induce strong CD3~'phosphoryhtion (52). Furthermore, these 
events may also underlie the function of analog peptides that 
act as TCR antagonists  (73). 
It might be tempting to conclude from these data that phos- 
phorylation of CD3~'is not sufficient to induce T cell activa- 
tion. However, it has been shown dearly that the cytoplasmic 
domains of the  CD3~" chain alone can  induce activation 
(63-65),  and that its absence abrogates T cell function (74, 
75). Although the importance of CD3~" chain phosphoryla- 
tion has been brought into question (76), these events strongly 
correlate with T cell activation (74, 77). In total, these findings 
suggest that the ability of CD3~" to activate T cells is regu- 
lated when it forms part of the TCR-CD3 complex but not 
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when it is present on its own. Furthermore, they question 
the speculation that the multiple signal transduction pathways 
which emanate from the TCR-CD3 complex merely repre- 
sent redundancy (62). Alternatively, these multiple pathways 
may provide the TCR with the unique capacity to respond 
differently depending on the ligand presented. Whatever the 
mechanism, it is clear that single amino acid substitutions 
in the flanking regions of core epitopes can have a dramatic 
effect on TCR recognition in the absence of CD4. This ob- 
servation alone could have significant consequences for our 
understanding of TCR recognition and may provide an ex- 
planation for why especially long peptides  are required to 
stimulate  high affinity T  cell responses (78). 
What Is the Role of CD4 in this Process?  It is interesting 
to question why the TCR needs CD4 in order to respond 
to peptides lacking the Trp residues. Although CD4 was ini- 
tially suggested to play an adhesion role (79, 80), many have 
argued that this requirement cannot adequately explain its 
function (39, 81). Indeed, routine CD4 was recently shown 
to have an affinity for MHC class II molecules even lower 
than that of the TCK (K~ ~  104 M-1; 82). However, it is 
still possible that this low affinity interaction is sufficient to 
compensate for any increased affinity afforded by the TCR 
binding directly to Trp 62 and Trp 63. It has also been sug- 
gested that signal transduction via CD4 is important for effec- 
tive T  cell activation  and selection (39, 41, 83).  However, 
the response of loss variants transfected with CD4 cytoplasmic 
tailless mutants is comparable with the response of wild-type 
CD4 transfectants. Taken together, these data raise the possi- 
bility that the physical  interaction between CD4 and the TCR 
improves the quality of signaling via the TCR, and that this 
involves the external CD4 domains.  Indeed, both physical 
and functional interaction of the D3/D4 domains of CD4 
and the TCR-CD3 complex has recently been shown (Vig- 
nali, D. A. A., R. Mittler, and J. L. Strominger,  unpub- 
lished data). 
Conclusions.  The data presented here dearly demonstrate 
that the amino acids which flank the core MHC class II 
binding epitope of HEL 52-61 have  a profound effect on TCR 
recognition and that this deficiency can be compensated for 
by the extracellular domains of CD4, thereby defining a novel 
role for this molecule. Furthermore, TCR ligation and CD3~" 
phosphorylation proceed normally despite a complete lack 
of IL-2 production, and minimal IP production and PLC3,1 
phosphorylation. In fact, the latter can only be induced by 
CD4 or the appropriate peptide-flanking residues. Although 
there have been several reports in which single amino acid 
substitutions resulted in differential signaling  through the 
TCR (49, 50, 73), this is, to our knowledge, the first obser- 
vation involving peptides known to be naturally processed 
by APCs (46, 47).  Indeed, of the 16 peptides  that contain 
the core sequence 52-61 and that were recently identified from 
HEL-pulsed,  H-2A  k positive B cells, 10 contain Trp 62 and 
Trp 63 (47). 
Several studies have demonstrated that flanking residues 
are critical for T cell recognition of some, but not all, clones 
(84-86).  However,  these observations  are probably due to 
differences  in TCR-VotVB usage, whereas in the present study, individual TCKs are studied in the presence  or absence of 
CD4. Thus, CD4 may play an important role in reducing 
the TCKs "intolerance" to peptide NH2- and COOH-ter- 
minal variability. 
Considerable differences exist between the structures of 
CD4 and CD8 (87-89), and the characteristics of MHC class 
I and II bound peptides.  In light of the data presented here, 
it is tempting to speculate  that the present CD4 structure 
may have evolved to ensure that the TCR could recognize 
all naturally processed peptides bound by MHC dass II mol- 
ecules. 
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